Illness	Number of cases
Intracranial injury (S06.0)	117
Other special examinations and investigations of persons without complaint or reported diagnosis (Z01.5)	63
Disorders related to short gestation and low birth weight not elsewhere classified (P07.12)	59
Diarrhoea and gastroenteritis of presumed infectious origin (A09.9)	54
Acute upper respiratory infections of multiple and unspecified sites - Acute upper respiratory infection unspecified (J06.9)	52
Acute bronchitis - Acute bronchitis unspecified (J20.9)	50
Acute upper respiratory infections of multiple and unspecified sites (J06.8)	48
Pneumonia organism unspecified - Bronchopneumonia unspecified organism (J18.0)	45
Adverse effects not elsewhere classified (T78.1)	45
Other functional intestinal disorders - Other constipation (K59.09)	38

Top 10 treatments

Treatment	Number
Measurement of brain waves triggered by targeted stimuli (evoked potentials) (1-208.1)	278
Computer-assisted analysis of the images with 3D-analysis (3-990)	234
Intensive care monitoring of respiration, the heart and the circulation without measurement of the pressure in the pulmonary artery and in the right atrium of the heart (8-930)	233
Quantitative analysis of specific values such as organ function or blood flow rate (3-993)	217
Investigation of an allergy by specifically triggering an allergic reaction (1-700)	194
Magnetic resonance imaging (MRI) of the head without contrast medium (3-800)	190
Administration of medicines or salt solutions through the blood vessels in newborn babies (8-010.3)	180
Other magnetic resonance imaging (MRI) without contrast medium (3-80x)	178
Measurement of the brain waves - EEG (1-207.0)	122
(8-98g.10)	115

Further information about the department

Out-patient accident insurance doctor approval

In-patient Employers’ Liability Insurance Association approval

Department key

Department key: 1000

Type of specialist department

Main Department

Hospital information and services for all specialist departments

Services

Quality

External comparative quality assurance

Further information

External quality assurance according to state law
No participation

Quality of participation in the Disease Management Programme (DMP)
No participation

Teilnahme an sonstigen Verfahren der externen vergleichenden Qualitätssicherung

Implementation of resolutions of the Federal Joint Committee on quality assurance (G-BA)

No.	Explanation
CQ02
CQ05

Further training
pursuant to Article 136b, para. 1, sentence 1, no. 1 of the SGB

Number	Group
9	Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
7	Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
4	Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations

* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

Accessibility

Accessibility information

General information

Research & teaching

Job	Explanation
Doctoral supervision	Abschluss einer Dissertation für Uni Jena 10.2023 (Prof. Mainz) 5 DoktorandInnen der MHB (Prof. Mainz)
Student training (clinical traineeship / internship year)	14 Famulanten und 3 PJler auf Stationen der Kinderklinik KWB-Brandenburg
Lectureships / teaching posts at universities of applied sciences
Lectureships / teaching posts at colleges and universities	Prof. Mainz, berufen W2-MHB; Chefarzt Dr. Kössel Vorlesungen MHB; Oberärzte der Kinderklinik: Kurse für Pädiatrie 5. und 8. Semester MHB
Editors of scientific journals/textbooks	Prof. Dr. J.G. Mainz: 8 Artikel in internationalen Peer-Reviewed Journals
Project-related cooperation with colleges and universities	Kooperationspartner für Studien mit CFAbd-Score: D: Potsdam, Uni Frankfurt, Gießen, Tübingen International: Sydney, Toronto, Dublin (Irl.), London, Leeds, Nottingham (UK), Paris (F), Zürich (CH), Ghent (Belgien), Thessaloniki (Griechenland), Campinas (Brasilien), Santa Fe (Argentinien)
Participation in multi-centre phase III/IV studies	Principal Investigator: VX20-CFD-005; VX21-445-123: Co Investigator; 2021-000190-81: Principal Investigator; 2020-005805-25: Co-Investigator; 2021-000712-31: Co-Investigator